Fatty acid binding protein 3 as a potential mediator for diabetic nephropathy in eNOS deficient mouse  by Ozawa, Shota et al.
Biochemical and Biophysical Research Communications 454 (2014) 531–536Contents lists available at ScienceDirect
Biochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate /ybbrcFatty acid binding protein 3 as a potential mediator for diabetic
nephropathy in eNOS deﬁcient mousehttp://dx.doi.org/10.1016/j.bbrc.2014.10.121
0006-291X/ 2014 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
⇑ Corresponding author at: TMK project, Medical Innovation Center, Kyoto
University, 53 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan. Fax: +81 75 751
4158.
E-mail address: nakagawa@tmk.med.kyoto-u.ac.jp (T. Nakagawa).Shota Ozawa a,b, Shuko Ueda a,c, Ying Li a, Kiyoshi Mori a, Katsuhiko Asanuma a, Motoko Yanagita a,d,
Takahiko Nakagawa a,⇑
a TMK Project, Medical Innovation Center, Kyoto University, Kyoto, Japan
b Pharmacology Research Laboratories II, Mitsubishi Tanabe Pharma Corporation, Saitama, Japan
cDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
dDepartment of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan
a r t i c l e i n f o a b s t r a c tArticle history:
Received 22 October 2014
Available online 30 October 2014
Keywords:
Fatty acid
Endothelial
Inﬂammation
Nitric oxide
Advanced diabetic nephropathy
FABPIn human diabetic nephropathy, glomerular injury was found to comprise lipid droplets, suggesting that
abnormal lipid metabolism might take place in the development of diabetic glomerular injury. However,
its precise mechanism remains unclear. Fatty acid binding protein (FABP) is currently considered as a key
molecule for lipid metabolism. Since diabetic eNOS knockout (KO) mouse is considered to be a good
model for human diabetic nephropathy, we here investigated whether FABP could mediate glomerular
injury in this model. We found that glomerular injuries were associated with inﬂammatory processes,
such as macrophage inﬁltration and MCP-1 induction. Microarray assay with isolated glomeruli revealed
that among 10 isoforms in FABP family, FABP3 mRNA was most highly expressed in diabetic eNOSKO
mice compared to non-diabetic eNOSKO mice. FABP3 protein was found to be located in the mesangial
cells. Overexpression of FABP3 resulted in a greater response to palmitate, a satulated FA, to induce
MCP-1 in the rat mesangial cells. In turn, the heart, a major organ for FABP3 protein in normal condition,
failed to alter its expression level under diabetic condition in either wild type or eNOSKO mice. In con-
clusion, FABP3 is induced in the mesangial cells and likely a mediator to induce MCP-1 in the diabetic
nephropathy.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
A lack of insulin action which stems from either insulin deﬁ-
ciency or insulin resistance causes diabetes. While a major feature
of diabetes is the hyperglycemia, an increase in serum fatty acid
(FA) could be another feature in diabetes. A lack of insulin function
induces lipolysis and then releases the FA into circulation from
white adipose tissue. FA is usually a source of energy for several
types of cells in case of hypoglycemia whereas an excess amount
of FA is likely problematic in our body. In fact, several studies indi-
cate that serum FA could be involved in inﬂammation, endothelial
dysfunction, and insulin resistance [1]. Several mechanisms for the
deleterious effects of FA have been proposed. An interesting mech-
anism could be a perturbation of plasma FA composition which
could be an unbalance of satulated FA with unsatulated FA becausesuch unbalance was found to be associated with the metabolic syn-
drome and low grade inﬂammation in overweight adolescents [2].
In kidney, free FA bound to albumin could be ﬁltered through
glomeruli in vivo, and stimulate the cultured proximal tubular epi-
thelial cells to release MCP-1 [3].
FA serves such roles to maintain physiological cellular function
as membrane phospholipid constituents, metabolic substrates,
precursors for intracellular signaling molecules and mediators for
gene expressions. As such, it is likely that the highly sophisticated
mechanism must be required for FA metabolism and such mecha-
nism would be regulated by several factors. In these processes, the
fatty acid binding proteins (FABPs) have been postulated to con-
tribute to the cellular FA transports and utilizations [4,5].
Diabetic nephropathy is characterized by unique glomerular
injuries, including Kimmelstiel–Wilson nodule, mesangiolysis and
glomerular microaneurysm. Interestingly, nodular lesions were
found to comprise the lipid droplets [6], suggesting that diabetic
glomerular injury might be involved in lipid abnormalities.
Recently, we and others have reported that diabetic eNOS knock-
out (KO) mice featured some types of glomerular injuries resemble
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(1) if FABP is involved in the development of glomerular injury,
and (2) if it is the case, what is the function of FABP in the devel-
opment of glomerular injury in the diabetic eNOSKO mice.2. Materials and methods
2.1. Experimental protocols
All animal experiments were performed in accordance with the
Animal Experimentation Committee of Kyoto University and Tana-
be R&D Service Co., Ltd. (Osaka, Japan). Male C57BL/6J-Nos3tm1nc
(eNOSKO) mice and C57BL/6J (WT) mice at 7 weeks of age were
purchased from Jackson Laboratory (Bar Harbor, ME) or Charles
River Laboratories (Wilmington, MA), respectively. Diabetes was
induced in both types of mice with intraperitoneal injection of
50 mg/kg/day streptozotocin for ﬁve consecutive days. Diabetes
was deﬁned as non-fasting blood glucose > 250 mg/dl using a
blood glucose meter. Mice were fed a standard laboratory chow
ad libitum. Mean blood pressure was measured using CODA
Multi-Channel, Computerized, Non-Invasive Blood Pressure Sys-
tem (Kent Scientiﬁc Corporation, Torrington, CT) while blood glu-
cose level were determined by GLUCOCARD MyDIA (Arkray,
Edina, MN). Urine was collected overnight using metabolic cages.
At 20 weeks of age, all mice were sacriﬁced to obtain blood, kidney
and heart.
2.2. Laboratory studies
Urine albumin was measured with Albuwell M (Exocell, Phila-
delphia, PA). Urinary FABP3 was measured with CircuLex Mouse
FABP3/H-FABP ELISA Kit (CY-8055) (CycLex, Nagano, Japan). Serum
creatinine, total cholesterol, triglyceride and nonesteriﬁed FA were
measured by a commercial kit (Oriental Bioservice, Kyoto, Japan).
2.3. Isolation of glomeruli
Mice at 14 weeks of age were anesthetized by isoﬂurane
(Mylan, Washington County, PA) and perfused with 8  107 Dyna-
beads (Life technology, Waltham, MA) diluted in 40 ml of Hank’s
Balanced Salt Solution through the heart. Kidneys were isolated
and digested in collagenase solution (1 mg/ml collagenase A and
100 U/ml deoxyribonuclease I) for 30 min at 37 C, and then
glomeruli containing Dynabeads were gathered by a magnetic par-
ticle concentrator. During the procedure, kidney tissues were kept
at 4 C except for the collagenase digestion at 37 C. Glomeruli
were lysed with 350 lL of lysis buffer to extract RNA.Table 1
General characteristics.
Characteristic WT
NDM (N = 10) DM (
Blood glucose (mg/dl) 114.7 ± 15.6 435.3
Mean BP (mmHg) 93.7 ± 5.8 99.6
Urine albumin (lg/day) 2.6 ± 1.2 18.7
Serum creatinine (mg/dl) 0.09 ± 0.02 0.09
T.CHO (mg/dl) 111.0 ± 16.0 118.3
TG (mg/dl) 93.2 ± 30.7 100.5
NEFA (lEq/L) 865.2 ± 149.5 933.3
T.CHO, total cholesterol; TG, triacylglycerol; NEFA, non esteriﬁed fatty acids.
a p < 0.001 vs. NDM WT.
b p < 0.001 vs. NDM eNOSKO.
c p < 0.05 vs. NDM WT.
d p < 0.01 vs. NDM WT.
e p < 0.01 vs. DM WT.2.4. Microarray analysis
Glomerular RNA was extracted and puriﬁed with RNeasy Mini
Kit (Qiagen, Chatsworth, CA) before RNA quality was assessed with
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). In
accordance with the Agilent Technologies protocol, all samples
were processed and a total of 480 ng of probe was hybridized to
SurePrint G3 Mouse Gene Expression 8  60 K (Agilent Technolo-
gies). Fluorescence was detected using G2539A Scanner (Agilent
Technologies). The data was analyzed with GeneSpring GX (Agilent
Technologies).
2.5. Histological analysis
Formalin-ﬁxed parafﬁn-embedded sections (2 lm) were
stained with the periodic acid-Schiff reagent (PAS) on coronal sec-
tions of the kidney for light microscopy. All glomeruli (50–100
glomeruli) were evaluated for mesangial expansion, mesangiolysis
and glomerulosclerosis. These abnormalities were evaluated as
previously reported [7].
2.6. Immunohistochemistry and immunoﬂuorescence
Formalin-ﬁxed, parafﬁn-embedded sections were used for
immunohistochemistry as previously described [8]. The following
antibodies were used as primary antibodies: (1) rabbit anti FABP3
antibody (Abcam, Cambridge, UK), (2) goat anti SMA antibody
(Abcam), and (3) goat anti SM22 antibody (LSBio, Seattle, WA).
Double immunoﬂuorescence staining was performed for FABP3
with either SMA or SM22. Brieﬂy, the deparafﬁnization of the sec-
tions was incubated with 5% donkey serum for 1 h and then with
primary antibodies overnight at 4 C. After incubation with Alexa
Fluor 488-labeled donkey anti rabbit IgG (Invitrogen, Carlsbad,
CA) and Alexa Fluor 568-labeled donkey anti goat IgG (Invitrogen)
for 1 h at room temperature, sections were mounted with vecta-
shield anti-fade mounting medium (Vector, Burlingame, CA). Sin-
gle immunoﬂuorescence staining for FABP3 was performed using
ImmPRESS REAGENT KIT (Vector). In turn, frozen sections (4 lm)
were used for immunoﬂuorescence staining for CD68 with mouse
anti-CD68 (Abcam). CD68 inﬁltration was determined by ratio of
CD68 positive area to glomeruli area. Areas were measured using
MetaMorph (Molecular Devices, Sunnyvale, CA).
2.7. Quantitative polymerase chain reaction (qPCR)
The ﬁrst strand cDNA was synthesized from 1 lg of total RNA
using ReverTra Ace a (TOYOBO, Osaka, Japan). Several sets of
primers were used to detect mRNA expressions. Amount of PCReNOSKO
N = 12) NDM (N = 10) DM (N = 13)
± 118.2a 116.4 ± 21.8 569.3 ± 83.3a,b
± 10.4 107.4 ± 9.4c 108.5 ± 11.3d
± 13.7 39.9 ± 31.1 595.1 ± 319.9a,b,e
± 0.02 0.10 ± 0.01 0.14 ± 0.03a,b
± 7.1 108.7 ± 10.4 161.3 ± 48.5a,b,e
± 49.4 112.2 ± 50.1 76.0 ± 37.3
± 193.8 736.1 ± 116.6 921.8 ± 305.4
WT
DM-eNOSKO
DM-WT
eNOSKO
P<0.001
Mes Exp
Mesangiolysis
Glom Scl
P<0.01
CD68
P<0.05
P<0.01
P<0.001
MCP-1
P<0.001 P<0.001
P<0.001 P<0.001 P<0.001
P<0.001 P<0.001 P<0.01
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Fig. 1. Glomerular injury is associated with inﬂammation in diabetic eNOSKO mouse. PAS staining shows that mesangial expansion is prominent in diabetic (DM) eNOSKO
mouse compared to WT, DMWT, and eNOSKO mouse (A). Glomerular CD68 signals appear to be increased in DM eNOSKO mouse compared to other mice (A). Quantiﬁcation
of glomerular injury using PAS staining is shown for mesangial expansion (Mes Exp) (B), mesangiolysis (C), and glomerulosclerosis (Glom scl) (D). % positive area for CD68 in
glomerulus is shown in (E). MCP1 mRNA expression in isolated glomeruli is shown in (F). NDM, non diabetes; DM, diabetes; Each column consists of mean ± SD. Scale bar,
50 lm.
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Following primers were used; 18S rRNA, AGGGGAGAGCGGGTAA-
GAGA (forward (FW)) and GGACAGGACTAGGCGGAACA (reverse
(RV)); mouse MCP1, AGGTCCCTGTCATGCTTCTG (FW) and TCTGGA
CCCATTCCTTCTTG (RV); mouse FABP3, CTTTGTCGGTACCTGGAAGC
(FW) and TGGTCATGCTAGCCACCTG (RV); rat actin, CACCCGCGA
GTACAACCTTC (FW) and CCCATACCCACCATCACACC (RV); rat
MCP1 ATGCAGTTAATGCCCCACTC (FW) and TTCCTTATTGGGGT-
CAGCAC (RV).
2.8. Western blotting
Kidney cortex and heart were homogenized and lysed directly
with RIPA buffer. Brieﬂy, samples were processed with SDS–PAGE,
and electrotransferred onto a PVDF membrane. After overnight
incubation with primary antibody at 4 C, membrane was
incubated with secondary antibody for 1 h at room temperature.
ECL Prime (GE Healthcare, Buckinghamshire, England) was
added to detect bands and ﬁgures were shown by Image QuantLAS4000mini (GE Healthcare). FABP3 (Abcam), GAPDH (Millipore)
and b actin (SIGMA–ALDRICH, St. Louis, MO) were used as primary
antibody. Anti-Mouse HRP (GE Healthcare) and Anti-Rabbit HRP
(GE Healthcare) were used as secondary antibody.2.9. Construction of adenoviral vector
The complementary DNA encoding the full length mouse FABP3
protein was ampliﬁed from mouse kidney cDNA. We used the
sense primers GGGGACAAGTTTGTACAAAAAAGCAGGCTGCCACCAT
GGCGGACGCCTTTGTCGGTAC and the antisense GGGGACCACTTTG-
TACAAGAAAGCTGGGTCTCACGCCTCCTTCTCATAAGTCCG to insert
mouse FABP3 gene into donor vector (pDONR221), and induce
the recombination reaction for pAd CMV FABP3. The recombinant
adenovirus backbone was linearized by digestion with PacI and
infected to 293A cells for packing to obtain recombinant protein.
The titer was estimated using Adenovirus Hexon Polyclonal HRP
conjugate Antibody (Thermo Fisher Scientiﬁc, Waltham, MA). An
FABP3 mRNA
P<0.01 P<0.001 P<0.01 P<0.001
Urinary FABP3
OKSONeMDTW eNOSKO
Glom FABP3
Glomerular mRNA
P<0.001 P<0.001 P<0.001
DM-WT
FABP3
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Fig. 2. FABP3 expression in glomerulus of diabetic eNOSKO mice. Microarray analysis demonstrates that FABP3 mRNA is most abundantly expressed in glomeruli of diabetic
(DM) eNOSKO mice compared to non diabetic (NDM) eNOSKO mice (A). Western blotting shows that FABP3 protein in the renal cortex is increased in DM-WT mice and
appears to be the highest in DM eNOSKO mice (B). In contrast, FABP3 protein expression in the heart shows no change in either diabetes or eNOS deﬁciency (B). FABP3 mRNA
expressions in renal cortex (C), urinary FABP3 protein/creatinine ratio (D), and glomerular FABP3 mRNA expression (E) are shown. Immunohistochemistry demonstrates that
FABP3 protein appears to be prominent with the mesangial pattern in glomerulus of DMeNOSKO mice (F). Each column consists of mean ± SD. Scale bar, 50 lm.
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as control.
2.10. FFA assay
Rat mesangial cells (RMC) (ATCC, Manassas, VA) in RPMI1640
with 10% fetal bovine serum (FBS) were infected by adenovirus
for 1 h, then medium was replaced with RPMI1640 with 0.5%
FBS. After 31 h, palmitate, a satulated FA, was added into medium.
Cells were incubated for 16 h and harvested for Western blotting
and qPCR. Sodium palmitate (Sigma) was dissolved in 50% ethanol
and mixed vigorously with 12.5% FFA-free BSA in PBS.
2.11. Statistical analysis
All values are expressed as mean ± SD. Statistical analysis was
performed with ANOVA using Tukey’s method to compare four
groups. A level of p < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. General characteristics
Streptozotocin induced marked hyperglycemia in both wild
type (WT) and eNOSKO mice. A lack of eNOS was associated with
higher blood pressure whereas such tendency was maintained
after STZ injection. Renal function was reduced as serum creatinineas well as urinary albumin excretion was signiﬁcantly elevated in
diabetic eNOSKO mice compared to other groups. In terms of lipid
proﬁle, serum cholesterol was also higher in diabetic eNOSKO mice
than that in other mice while serum triglyceride did not show any
signiﬁcant difference between groups. Diabetic condition tended to
increase non esteriﬁed FA (NEFA) in both WT and eNOSKO mice
while it did not reach signiﬁcance (Table 1).
3.2. Glomerular histology
As reported previously [7], diabetic wild type mice exhibited
mesangial expansion while severer glomerular injuries, such as
mesangiolysis and glomerulosclerosis were induced under diabetic
condition in eNOSKO mice (Fig. 1A–D). With respect to inﬂamma-
tion, CD68, a macrophage marker, and MCP-1 were also higher in
glomeruli of diabetic eNOSKO mice compared to wild type mice
(Fig. 1E and F).
3.3. Involvement in FABP3 in diabetic nephropathy
Microarray analysis using glomerular mRNA showed that
among 10 isoforms, FABP3 mRNA expression was most abundantly
expressed in diabetic eNOSKO compared with non diabetic eNO-
SKO mice (Fig. 2A). FABP3 protein in the renal cortex appeared to
be induced under diabetic condition while the expression level
appeared to be the highest in diabetic eNOSKO mice compared to
mice in other groups (Fig. 2B). Such pattern was mirrored to that
FABP3
FABP3
SMA
SM22
Merge
Merge
Lac Z   FABP3
FABP3
Actin
R²=0.634
P<0.001
P<0.01 P<0.01
P<0.05
A B
C D
Fig. 3. Mesangial FABP3 causes inﬂammation. Immunoﬂuorescence demonstrates that FABP3 is overlapped with a-smooth muscle actin (SMA) and SM22 (A). In mRNA
expression, association of MCP-1 with FABP3 is found to be positive in this study (B). Rat mesangial cells with Adenovirus coding FABP3 show FABP3 protein expression in
contrast to cells with adenovirus coding LacZ, as a control (C). MCP-1 mRNA expression in response to 150 lM palmitate in rat mesangial cells is shown (D). Each column
consists of mean ± SD. Scale bar, 50 lm.
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level (Fig. 2D). An increase in glomerular mRNA induction was
likely more speciﬁc in diabetic eNOSKO mice compared to other
groups (Fig. 2E), and such tendency was also conﬁrmed by immu-
nohistochemistry. In addition, FABP3 protein likely showed the
mesangial pattern (Fig. 2F). In turn, FABP3 is known to be domi-
nantly expressed in the heart, and therefore we examined the level
of FABP3 in the heart of this animal model. However, the heart did
not show any response to diabetic condition in either wild type or
eNOSKO mice (Fig. 2B).
3.4. Mesangial FABP3 for MCP-1 expression
FABP3 was predominantly overlapped with smooth muscle
actin and sm22, both of which are markers for injured mesangial
cells [9]. Since free FA was reported to induce MCP-1 expression
[3], we examine the association of FABP3 with MCP-1 expression
in isolated glomeruli from diabetic eNOSKO mice. As shown in
Fig. 3B, we found a positive association between FABP3 mRNA
and MCP-1 mRNA in the isolated glomeruli of this model. In the
cultured rat mesangial cells, we induced FABP3 protein using ade-
novirus system to examine the role of FABP3 (Fig. 3C). We found
that an induction of MCP-1 in response to palmitate was signiﬁ-
cantly enhanced by an overexpression of FABP3 (Fig. 3D). It is
interesting to note that angiogensin II (108–106M), high glucose
(30 mM), TGF-b (0.2–20 ng/ml), and palmitate (30–150 lM) failed
to induce FABP3 mRNA in the rat mesangial cells (data not shown).
4. Discussion
An increase in serum FA accompanied with hyperglycemia
could be another risk factor for the development of diabetic
nephropathy. FA is generally metabolized by sophisticated mecha-
nisms in which FABPs play a key role in its metabolism. Currently
10 FABP isoforms have been identiﬁed, and we found that FABP3
was most dominantly and signiﬁcantly induced in glomeruli ofdiabetic eNOSKO mice compared to non-diabetic eNOSKO mice.
Interestingly, it was found that mesangial cell was capable of
inducing FABP3 in the glomerulus of this mouse model. The
up-regulated FABP3 likely contributed to develop glomerular
inﬂammation as overexpression of FABP3 in the mesangial cells
was proved to enhance the MCP-1 induction in response to free
FA in the cultured mesangial cells. Consistently, FABP3 expression
was associated with MCP-1 expression and CD68 cells inﬁltration
in glomerular injury of this animal model.
Human diabetic nephropathy is characterized by several types
of glomerular injuries, including nodular sclerosis, mesangiolysis
and capillary microaneurysm. However, precise mechanisms for
such injuries remain unknown. Interestingly, electronic micros-
copy demonstrated that nodular lesions were composed of multi-
ple factors, including lipid droplet [6]. Likewise, both Akita
mouse and db/db mouse were found to develop lipid depositions
in the glomerulus as the disease progressed [10,11]. A mechanism
for the lipid deposition was due in part to an increase in FA synthe-
sis in the diabetic kidney [10,11]. These data suggest that an
increase of FA levels in serum and kidney could mediate the devel-
opment of diabetic glomerular injury. However, it remains unclear
as to how FA mediates the pathophysiological process in the dia-
betic nephropathy.
Implication of FA in the inﬂammatory response has been
studied by several investigators. For instance, an administration
of palmitate, a satulated FA, was found to be enhance diacylglyc-
erol levels in skeletal muscle cells, leading to activation of pro-
tein kinase C/NFjB pathway [12]. Likewise, the proximal
tubular epithelial cells showed a response to palmitate to induce
MCP-1 [3]. Consistently, a clinical study found the positive asso-
ciation of plasma FA with low grade inﬂammation in overweight
adolescents [2]. In this study, we found an induction of FABP3 in
glomeruli, in particular the injured mesangial cells of diabetic
eNOSKO mice. FA-induced MCP-1 induction was also enhanced
by an overexpression of FABP3 in mesangial cells. Consistently,
an accumulation of CD68, a marker of macrophage, and an
536 S. Ozawa et al. / Biochemical and Biophysical Research Communications 454 (2014) 531–536induction in MCP-1 expression were also associated with FABP3
expression. Perhaps, the mesangial FABP3 could cause inﬂamma-
tion in diabetic condition.
FABPs are small, highly-expressed proteins that reversibly
bind to FA and other lipophilic molecules. FABP which locates
on plasma membrane are able to facilitate FA uptake into cells
while intracellular FABPs can transport FA to other locations,
including nuclear receptors. Distinct mechanisms could be oper-
ated in different organs and cells as 10 isoforms of FABPs are
distinctly distributed in various tissues in mammals [4]. Among
them, FABP3 is most predominantly expressed in the heart and
less in the skeletal muscle, kidney, stomach, and testis [4]. In
human kidney, there are two types of FABPs; one is FABP3 and
the other is FABP1 [13]. FABP1 is expressed in the proximal
tubular epithelial cells whereas FABP3 was found to be present
in the distal tubular epithelial cells [13]. Nonetheless, the fact
that FABPs are expressed in normal condition suggests that such
protein could be indispensable for maintaining physiological
condition in several types of cells or organs.
Recently, Nauta et al. have reported that there was a signiﬁcant
increase in urinary FABP3 concentration in diabetic patients, and
importantly such elevation in the urine was detected prior to the
onset of microalbuminuria [14]. Given the FABP3 expression in dis-
tal tubular epithelial cells, such elevation in urinary FABP3 would
be accounted for by the distal tubular damage. Here we showed
that the mesangial cells expressed FABP3, indicating that mesan-
gial cells could be another source of urinary FABP3 in diabetic
patients. As such, high in urinary FABP3 concentration could indi-
cate the distal tubular damages as well as the glomerular injury in
diabetic patients.
In conclusion, we found that FABP3 was induced in advanced
diabetic nephropathy in eNOSKO mice. Mesangial expression of
FABP3 could contribute to the induction of inﬂammatory response
in the process of diabetic glomerular injury in the mouse.
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